MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
IDEAYA Biosciences Long-Term Debt 2011-2025 | IDYA
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt IDEAYA Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.9 M | 1.12 M | 1.61 M | 3.48 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.9 M | 1.12 M | 6.27 M |
Quarterly Long-Term Debt IDEAYA Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.9 M | 26.3 M | 25.7 M | 18.9 M | 18.8 M | 1.26 M | 1.26 M | 1.12 M | - | 611 K | 1.12 M | 1.61 M | 2.1 M | 2.57 M | 3.03 M | 3.48 M | 3.92 M | 4.36 M | 4.77 M | 5.18 M | 5.18 M | 5.18 M | 5.18 M | 5.63 M | 5.63 M | 5.63 M | 5.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.9 M | 611 K | 7.35 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
1.82 M | $ 4.95 | 4.99 % | $ 822 M |  Canada |
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
2.12 M | $ 3.2 | -1.48 % | $ 247 M |  USA |
 |
AlloVir
ALVR
|
16.6 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
4.63 M | $ 1.06 | -5.97 % | $ 293 K | USA |
 |
Catalyst Biosciences
CBIO
|
199 K | $ 13.19 | -6.39 % | $ 868 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
59.9 K | $ 3.1 | -5.93 % | $ 7.46 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
2.36 M | $ 27.04 | -1.73 % | $ 1.74 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
6.11 M | $ 87.29 | -0.8 % | $ 9.01 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.79 M | $ 24.46 | 3.56 % | $ 2.9 B | USA |
 |
CureVac N.V.
CVAC
|
25.4 M | $ 5.04 | -0.3 % | $ 938 M | Germany |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
275 K | $ 1.43 | -1.38 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
26.4 M | $ 10.87 | 0.63 % | $ 1.41 B | USA |
 |
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.9 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
231 M | $ 94.19 | -0.66 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
9.62 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
614 M | $ 26.28 | 4.0 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
26.9 M | $ 9.64 | 0.84 % | $ 141 M | USA |
 |
Eton Pharmaceuticals
ETON
|
5.38 M | $ 15.96 | -4.43 % | $ 409 M | USA |
|
Foghorn Therapeutics
FHTX
|
28.1 M | $ 4.39 | -1.13 % | $ 241 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
14.7 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
8.76 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
188 K | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
41.4 M | $ 548.77 | -2.75 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
10.9 M | $ 2.36 | 2.61 % | $ 14.8 M | USA |
 |
AstraZeneca PLC
AZN
|
17.5 B | $ 91.51 | 1.87 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
166 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
627 M | $ 11.28 | -2.17 % | $ 730 M | USA |
 |
Biogen
BIIB
|
6.3 B | $ 174.19 | 0.05 % | $ 25.4 B | USA |
 |
Abeona Therapeutics
ABEO
|
4.4 M | $ 5.07 | -5.5 % | $ 108 M | USA |